Core Viewpoint - Jiayou Bio-B (06998) has submitted a listing application to the Hong Kong Stock Exchange, marking the first reverse acquisition case of an innovative pharmaceutical company since the implementation of Rule 18A by the Hong Kong Stock Exchange [1] Group 1: Company Overview - Yiteng Pharmaceutical is a comprehensive professional biopharmaceutical company that has established a competitive and market-potential portfolio of original and innovative drugs through acquisitions of brand drug assets from multinational companies [1] - The product portfolio of Yiteng Pharmaceutical includes five main products, three of which are original products (Wenkexin, Xikelai, and Yirui Ping) and two innovative products (Vascepa and Mulpleta), all of which have been commercialized [1][2] Group 2: Financial Performance - Yiteng Pharmaceutical's revenue for the years ending December 31, 2022, 2023, and 2024 is projected to be 2.0738 billion, 2.3038 billion, and 2.5460 billion respectively, indicating steady sales growth driven by the strong performance and potential of its product portfolio [5] Group 3: Strategic Implications - The integration of Jiayou Bio's innovative R&D resources will enable Yiteng Pharmaceutical to accelerate the development and market promotion of innovative drugs, particularly the upcoming CDK4/6 inhibitor, which can synergize with Yiteng's existing HDAC inhibitor to explore broader market opportunities [5]